UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.095

Sortiert nach

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Neurology, 2004-11, Vol.63 (9), p.1586

2004

Link zum Volltext

Verfügbarkeit prüfen

Vitamin D and multiple sclerosis-from epidemiology to prevention

Acta neurologica Scandinavica, 2015-07, Vol.132 (S199), p.56-61

2015

Link zum Volltext

Verfügbarkeit prüfen

An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study

Neurology, 2004-06, Vol.62 (12), p.2277

2004

Link zum Volltext

Verfügbarkeit prüfen

Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis

Brain (London, England : 1878), 2024, Vol.147 (1), p.177-185

2024

Link zum Volltext

Verfügbarkeit prüfen

Managing Epstein‐Barr virus and other risk factors in MS—Future perspectives

Acta neurologica Scandinavica, 2017-11, Vol.136 (S201), p.31-33

Sundstrom, P

2017

Link zum Volltext

Verfügbarkeit prüfen

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.352

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.638

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.858

2022

Link zum Volltext

Verfügbarkeit prüfen

Smoking and alcohol associated to the risk of developing Myasthenia gravis in a Swedish nationwide prevalent cohort

EUROPEAN JOURNAL OF NEUROLOGY, 2023, Vol.30 (Suppl. 1), p.54

2023

Link zum Volltext

Verfügbarkeit prüfen

Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis

MULTIPLE SCLEROSIS JOURNAL, 2022, Vol.28 (Suppl. 3), p.86

2022

Link zum Volltext

Verfügbarkeit prüfen

Prevention of post‐dural puncture headache: a randomized controlled trial

European journal of neurology, 2020-05, Vol.27 (5), p.871-877

2020

Link zum Volltext

Verfügbarkeit prüfen

Epstein-Barr virus and multiple sclerosis: interaction with HLA

Genes and immunity, 2012-01, Vol.13 (1), p.14-20

2012

Link zum Volltext

Verfügbarkeit prüfen

A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.536

2019

Link zum Volltext

Verfügbarkeit prüfen

A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.316

2019

Link zum Volltext

Verfügbarkeit prüfen

A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.327

2019

Link zum Volltext

Verfügbarkeit prüfen

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

Multiple sclerosis, 2014-02, Vol.20 (2), p.165-173

2014

Link zum Volltext

Verfügbarkeit prüfen

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.623

2021

Link zum Volltext

Verfügbarkeit prüfen

A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.616

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.612

2021

Link zum Volltext

Verfügbarkeit prüfen

Automated determination of brain parenchymal fraction in multiple sclerosis

American journal of neuroradiology : AJNR, 2013-03, Vol.34 (3), p.498-504

2013

Link zum Volltext

Verfügbarkeit prüfen

Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.763

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)

MULTIPLE SCLEROSIS JOURNAL, 2019, Vol.25 (Suppl. 2), p.316

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 5" (IMSE 5)

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.615

2021

Link zum Volltext

Verfügbarkeit prüfen

The long-term safety and effectiveness of natalizumab (IMSE 1) - Real-world data from a Swedish nationwide pharmaco-epidemiological study

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.618

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile

MULTIPLE SCLEROSIS JOURNAL, 2021, Vol.27 (Suppl. 2), p.626

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.095

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.024)
Mit Volltextzugriff
(969)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(729)
Life Sciences & Biomedicine
(598)
Humans
(482)
Medicin Och Hälsovetenskap
(432)
Female
(311)
Male
(243)
Biological And Medical Sciences
(213)
Adult
(191)
Middle Aged
(161)
Medical Sciences
(143)
Aged
(129)
Animals
(121)
Neurosciences & Neurology
(88)
Risk Factors
(85)
Oncology
(82)
Fundamental And Applied Biological Sciences. Psychology
(76)
Physical Sciences
(75)
Clinical Medicine
(71)
Medical And Health Sciences
(71)
Adolescent
(67)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Multiple Sclerosis
(24)
Acta Neurologica Scandinavica
(17)
Science
(16)
Multiple Sclerosis Journal
(14)
Plos One
(13)
The Journal Of Physical Chemistry. B
(13)
International Journal Of Cancer
(12)
Neurology
(12)
Blood
(11)
European Heart Journal
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Vitamin D and multiple sclerosis-from epidemiology to prevention

An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study

Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis

Managing Epstein‐Barr virus and other risk factors in MS—Future perspectives

Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)

Smoking and alcohol associated to the risk of developing Myasthenia gravis in a Swedish nationwide prevalent cohort

Increase in Epstein Barr virus serologies precedes neuroaxonal damage in pre-symptomatic multiple sclerosis

Prevention of post‐dural puncture headache: a randomized controlled trial

Epstein-Barr virus and multiple sclerosis: interaction with HLA

A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months

A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)

A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months

Cytomegalovirus seropositivity is negatively associated with multiple sclerosis

Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)

A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)

Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)

Automated determination of brain parenchymal fraction in multiple sclerosis

Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1)

Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)

Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 5" (IMSE 5)

The long-term safety and effectiveness of natalizumab (IMSE 1) - Real-world data from a Swedish nationwide pharmaco-epidemiological study

Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile

Suchergebnisse filtern